WonderFi Securityholders Approve Acquisition by Robinhood; Earnout Rights Holders Approve Amendments to Earnout Rights IndentureJuly 17, 2025 5:00 PM EDT | Source: WonderFi Technologies Inc.Toronto, Ontario--(Newsfile Corp. - July 17, 2025) - WonderFi Technologies Inc. (TSX: WNDR) (OTCQB: WONDF) (WKN: A3C166) ("WonderFi" or the "Company"), is pleased to announce that at its special meeting of shareholders (the "Shareholders") and holders of brokers warrants ("Brokers Warrants Holders", and tog ...

Senator Elizabeth Warren asked Treasury Secretary Scott Bessent and various ratings agencies for more information on risks posed by the $1.7 trillion private-credit industry https://t.co/FJs48bfES9 ...

Core Points - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly providing misleading information regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] - The lawsuit claims that Capricor made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [2] - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [3] - Following the CRL announcement, Capricor's stock price dropped from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [4] Company Information - Capricor Therapeutics is involved in developing cell therapies, specifically targeting conditions like cardiomyopathy associated with DMD [2] - The company faced significant challenges with the FDA regarding its lead drug candidate, deramiocel, which has implications for its future development and market potential [3] Legal Context - The class action lawsuit allows investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, to seek recovery for losses incurred due to the alleged misleading statements [1][4] - Investors have until September 15, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]

RT Bitcoin for Palestine ⚡⚡ (@Yusef_Mahmoud1)99% of the population of the Gaza Strip slept tonight without food or drink. The situation is very difficult. Oh God, relieve the suffering of the servants.https://t.co/gLV4RZ90xP🙏 ...

Core Points - Chemung Financial Corporation reported a net loss of $6.5 million, or $1.35 per share, for Q2 2025, contrasting with net income of $6.0 million, or $1.26 per share, in Q1 2025, and net income of $5.0 million, or $1.05 per share, in Q2 2024 [1] - The company undertook a balance sheet repositioning by issuing subordinated debt and selling a significant portion of its securities portfolio, which is expected to strengthen its regulatory capital position and improve funding flexibility [2] - Core operating results were solid, reflecting the resilience of the customer base and a disciplined organizational approach [3] Financial Performance - Net interest income for Q2 2025 was $20.8 million, up from $19.8 million in Q1 2025, marking a 5.0% increase driven by higher interest income on loans and interest-earning deposits [6] - Interest income on loans increased due to a $30.8 million rise in average loan balances and a 12 basis point increase in average yield on total loans [7] - Interest income on interest-earning deposits rose by $46.2 million in average balances, largely from proceeds of the securities sale and subordinated debt issuance [8] Balance Sheet Activity - Total assets increased to $2.852 billion as of June 30, 2025, up from $2.776 billion at the end of 2024, driven by increases in cash and cash equivalents and loans [38] - Total liabilities rose to $2.618 billion, primarily due to increases in total deposits and subordinated debt [42] - Total shareholders' equity increased to $235.0 million, reflecting a decrease in accumulated other comprehensive loss [46] Non-Interest Income and Expenses - The company recognized a pre-tax loss of $17.5 million on the sale of available for sale securities, leading to negative non-interest income of $10.7 million for the quarter [15] - Non-interest expense for Q2 2025 was $17.8 million, an increase of 5.3% from the prior quarter, driven by higher salaries, benefits, and professional services [18] Asset Quality - Non-performing loans totaled $8.2 million, or 0.39% of total loans, a decrease from $9.0 million, or 0.43%, at the end of 2024 [34] - The allowance for credit losses on loans was $22.7 million, reflecting an increase due to stronger loan growth and changes in economic forecasts [37] Market Position - The market value of total assets under management in the Wealth Management Group increased to $2.313 billion as of June 30, 2025, up from $2.212 billion at the end of 2024 [52] - The company completed the sale of a branch property, resulting in a pre-tax gain of $0.6 million, as part of its ongoing rationalization of physical distribution [53]

Core Viewpoint - A securities fraud lawsuit has been filed against Capricor Therapeutics, Inc. and certain executives, alleging false statements regarding the safety and efficacy of their drug candidate, deramiocel, leading to significant investor losses [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Capricor Therapeutics misled investors about deramiocel's progress towards FDA approval while concealing adverse data from the Phase 2 HOPE-2 trial [2]. - Following the release of negative information, Capricor's stock price experienced significant declines: from $10.30 to $7.30 on May 5, 2025; from $11.94 to $8.26 on June 20, 2025; and from $11.40 to $7.64 after the FDA's Complete Response Letter on July 11, 2025 [2]. Group 2: Eligibility and Actions - Investors who purchased Capricor common stock between October 9, 2024, and July 10, 2025, and have incurred losses may be eligible to participate in the lawsuit [3]. - The deadline to seek appointment as lead plaintiff is September 15, 2025, and investors are encouraged to contact Block & Leviton for further information [4]. Group 3: Whistleblower Information - Individuals with non-public information about Capricor Therapeutics are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].

RT Benny Johnson (@bennyjohnson)🚨BREAKING: The House has passed a bill to prevent the creation of a Central Bank Digital Currency (CBDC)219-210. https://t.co/SXhcLH2X6P ...

This article reports industry metrics, aiming at a top-down analysis of the consumer discretionary sector. It may also help analyze sector ETFs such as Consumer Discretionary Select Sector SPDR ETF ( XLY ) and Fidelity MSCI Consumer DiscretionaryFred runs the investing group Quantitative Risk & Value where he shares a portfolio invested in quality dividend stocks, and companies at the forefront of tech innovation. Fred also supplies market risk indicators, a real estate strategy, a bond strategy, and an inc ...

crypto bills on the Hill that we've been following. Emily Wilkins has the story. Hi, Emily.Hey, Morgan. Well, the House has now passed all three of those crypto bills. The one on market structure that will go to the Senate, the one on uh banning the central bank digital currency that will also go to the Senate, and of course, the one on stable coins.And that one is headed to the White House tomorrow to President Trump's desk. We're already hearing that there is expected to be a ceremony to sign it. Uh, that ...

The contours of Germany’s debate over Gaza—angry protests, university sit-ins, accusations that the government is abetting war crimes—resemble those elsewhere.But in the country responsible for the murder of 6m Jews, it carries extra weight https://t.co/ICIAM9VQdV ...